R

Ultragenyx Pharmaceutical
D

RARE

21.590
USD
-0.22
(-1.01%)
Market Closed
Volume
45,757
EPS
-4
Div Yield
-
P/E
-4
Market Cap
2,086,237,123
Overview
Related Instruments
A
ABEO
4.77000 USD
-0.20000
(-4.02%)
ALNY
ALNY
320.49 USD
1.65
(0.52%)
A
ARCT
6.40000 USD
-0.22300
(-3.37%)
BMRN
BMRN
56.020 USD
-1.430
(-2.49%)
C
CRSP
50.090 USD
1.650
(3.41%)
E
EDIT
2.46700 USD
-0.07800
(-3.06%)
F
FATE
1.13500 USD
-0.02500
(-2.16%)
N
NTLA
13.495 USD
0.100
(0.75%)
More

Title: Ultragenyx Pharmaceutical

Sector: Healthcare
Industry: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitatinggenetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated fromNorth America.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android
Social Network
The NetworkSignals NetworkIdeas NetworkBest TradersUser Reviews for Brokers
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHouse rulesHelp Centeradvertising with ArincenOur servicesReferral programDownload Mobile App
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.